Read the full article: ow.ly/kgOj50WS5sy #Anaesthesia #GLP1RA #EditorsChoice #MedicalResearch Editors Choice

AD: Alzheimers disease cAMP: cyclic adenosine monophosphate CSF: cerebrospinal fluid DPP-4: dipeptidyl-peptidase 4 DR: diabetic retinopathy GFAP: glial fibrillary acidic protein GLP-1: glucagon-like peptide 1 GLP-1R: glucagon-like peptide 1 receptor GLP-1RA: glucagon-like peptide 1 receptor agonist IIH: idiopathic intracranial hypertension IL-1beta: interleukin 1 beta NF-B: nuclear factor kappa B NO: nitric oxide PD: Parkinsons disease PINK1: protein phosphatase and tensin homolog-induced kinase 1 PKA: protein kinase A PPG: preproglucagon RGCs: retinal ganglion cells RPE: retinal pigment epithelium T2DM: type 2 diabetes mellitus TNF-alpha: tumor necrosis factor alpha VEGF: vascular endothelial growth factor Sohum S, AP, MF, MM, AR, RS, and Siddharth S: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writingoriginal draft
:max_bytes(150000):strip_icc()/diverticulosis-vs-diverticulitis-5201446-FINAL-2-1-a870abb4df9a4072b4888aa2273656bb.png)
Together, these form one of the body's most elegant metabolic control systems
The rationale is that even sub-therapeutic doses activate the GLP-1 and GIP receptors enough to produce noticeable appetite modulation without the gastrointestinal side effects that trouble many users during standard initiation
2024;47(Suppl 1):S20S42
Most data suggests it does not